Radiation Oncology In-service Exam Review: GI Cancers

10 Questions | By Mdaly | Updated: Mar 22, 2022 | Attempts: 3040

Questions

Settings

Create your own Quiz

Radiation Oncology In-service exam review: GI cancers

Questions and Answers

1.

Which major rectal cancer trial showed an overall survival benefit to pre-op radiation?
- A.
  
  German Rectal Cancer Trial (NEJM 2004)
- B.
  
  Dutch Colorectal Cancer Group (NEJM 2001)
- C.
  
  Swedish Rectal Cancer Trial (NEJM 1997)
- D.
  
  GITSG 7175
2.

What is the treatment of choice for gastric MALT?
- A.
  
  Low dose RT alone
- B.
  
  Chemotherapy alone
- C.
  
  Antibiotics directed at H. pylori
- D.
  
  Surgical resection followed by chemoradiation
3.

Via what drainage do rectal cancer metastases reach the liver?
- A.
  
  Superior rectal vein
- B.
  
  Inferior rectal vein
- C.
  
  Middle rectal vein
- D.
  
  Inferior mesenteric vein
4.

What was the chemoradiation used in the pre-op arm of the German Rectal Cancer Study (NEJM 2004)?
- A.
  
  50.4 Gy with concurrent Xeloda
- B.
  
  50.4 Gy with a 5.4 Gy boost with concurrent 5-FU
- C.
  
  54 Gy with concurrent 5-FU
- D.
  
  50.4 Gy with concurrent 5-FU
- E.
  
  25 Gy in 5 fractions with concurrent 5-FU
5.

What is the appropriate superior border of the PA field for a rectal cancer plan?
- A.
  
  L2-L3
- B.
  
  L5-S1
- C.
  
  L4-L5
- D.
  
  Top of obturator foramen
- E.
  
  L3-L4
6.

What is the appropriate dosing of concurrent 5-FU when given with RT for rectal cancer?
- A.
  
  225 mg/m2 over 24 hours, 7 days per week during RT
- B.
  
  150 mg/m2 over 24 hours, 7 days per week during RT
- C.
  
  250 mg/m2 over 6 hours, 7 days per week during RT
- D.
  
  250 mg/m2 over 12 hours, 5 days per week during RT
- E.
  
  225 mg/m2 over 12 hours, 5 days per week during RT
7.

Which of the following was a finding of the UKCCCR anal cancer trial working party (Lancet 1996?
- A.
  
  Chemoradation with 5-FU and mitomycin improved 3 year OS from 35 to 48% as compared to RT alone
- B.
  
  Chemoradiation with cisplatin and 5-FU improved LC from 36% to 59% as compared to RT alone
- C.
  
  Addition of post-op RT after surgery improved OS at 3 years from 35 to 48%
- D.
  
  Dose escalation from 45 Gy with 50.4 Gy improved LC from 36% to 59%
- E.
  
  Chemoradation with 5-FU and mitomycin improved 3 year LC from 36% to 59% as compared to RT alone
8.

What is Courvoisier's sign?
- A.
  
  Palpable tumor nodule at the umbilicus
- B.
  
  Palpable gallbladder
- C.
  
  Migratory thrombophlebitis
- D.
  
  Palpable axillary lymphadenopathy
9.

What was the randomization of the GITSG 91-73 trial for pancreatic cancer?
- A.
  
  Surgery alone vs surgery followed by chemoradiation with 54 Gy and concurrent 5-FU
- B.
  
  Definitive RT to 54 Gy versus Definitive CRT wtih 54 Gy and concurrent 5-FU
- C.
  
  Surgery alone vs surgery followed by chemoradiation with a 40 Gy split course followed by adjuvent gemcitabine
- D.
  
  Surgery alone vs surgery followed by chemoradiation with a 40 Gy split course and concurrent 5-FU
- E.
  
  Surgery alone vs surgery followed by radiation with a 40 Gy split course
10.

What was a major finding of the GITSG 91-73 trial for pancreatic cancer?
- A.
  
  Addition of adjuvent CRT with 5-FU and 40 Gy split course to surgery improved 5 yr OS from 5% to 14% in resectable pancreatic cancer
- B.
  
  Addition of adjuvent CRT with 5-FU and 40 Gy split course to surgery improved 5 yr LC but had no effect on OS.
- C.
  
  Addition of adjuvent RT with a 40 Gy split course to surgery improved LC at 2 years from 22% to 43%
- D.
  
  Addition of adjuvent gemcitabine to defintive RT for pancreatic cancer improved 1 year LC from 18% to 32%